Avanos Medical (NYSE: AVNS) director exits holdings in $25-per-share merger
Rhea-AI Filing Summary
Avanos Medical, Inc. director Lisa Egbuonu-Davis reported dispositions to the issuer in connection with the company’s merger effective July 27, 2026. She disposed of 13811 shares of common stock and 12003 restricted share units, each converted into the right to receive $25.00 per share in cash, leaving no holdings of these awards.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 13,811 shares
Net Sell
2 txns
Insider
Egbuonu-Davis Lisa
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Restricted Share Units F2, F3 | 12,003 | $25.00 | $300K |
| Disposition | Common Stock F1 | 13,811 | $25.00 | $345K |
Holdings After Transaction:
Restricted Share Units — 0 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.
- F2. Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock.
- F3. Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).
Key Figures
Common stock disposed: 13811 shares
Restricted share units canceled: 12003 units
Merger consideration per share: $25.00 per share
+2 more
5 metrics
Common stock disposed
13811 shares
Disposition to issuer in merger on July 27, 2026 at $25.00 per share
Restricted share units canceled
12003 units
Cash-settled RSUs converted to cash based on $25.00 per underlying share
Merger consideration per share
$25.00 per share
Cash paid for each share of common stock at effective time of merger
Post-transaction common stock holdings
0.0000 shares
Reported holdings of common stock following July 27, 2026 disposition
Post-transaction RSU holdings
0.0000 units
Reported holdings of restricted share units after cancellation in merger
Key Terms
Agreement and Plan of Merger, effective time of the merger, Merger Consideration, restricted share units, +1 more
5 terms
Agreement and Plan of Merger regulatory
"Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
effective time of the merger regulatory
"that was issued and outstanding immediately prior to the effective time of the merger"
The effective time of the merger is the exact moment when a planned combination of two companies legally takes effect, usually specified in the merger agreement and reflected by the formal filing or timestamp. For investors, it is the point when ownership, voting rights, financial reporting and control shift—like a light switch flipping that joins two rooms into one—so it determines when shares convert, who controls corporate decisions and which results appear in financial statements.
Merger Consideration financial
"was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration)"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Avanos Medical (AVNS) disclose in this Form 4?
Avanos Medical (AVNS) reported that director Lisa Egbuonu-Davis disposed of 13811 shares of common stock and 12003 restricted share units on July 27, 2026, in transactions coded as dispositions to the issuer tied to a merger closing.
Did the Avanos Medical (AVNS) director retain any of the reported equity after the merger?
For the positions reported, the director’s post-transaction holdings are shown as 0.0000 shares for both common stock and restricted share units. The filing indicates these specific awards were fully converted into cash rights in connection with the merger.
Was the Avanos Medical (AVNS) insider transaction an open-market sale?
No. The transactions are coded as dispositions to the issuer and tied to a merger. Shares and cash-settled restricted share units were converted into cash consideration of $25.00 per share under the merger agreement, rather than sold on the open market.